Outcome of board meeting held on 31-10-2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 1.2 pts more than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hindustan Bio Sciences reported weak H1 FY26 results with total revenue of Rs. 34.36 lakhs, down roughly 19% from Rs. 42.54 lakhs in H1 FY25, as Q2 FY26 had zero revenue from operations. The company swung from a profit of Rs. 3.16 lakhs in H1 FY25 to a loss of Rs. 4.45 lakhs in H1 FY26, with Q2 alone posting a loss of Rs. 5.85 lakhs versus a profit of Rs. 8.18 lakhs in the year-ago quarter. The balance sheet remains stressed with reserves and surplus in negative territory at Rs. (118.98) lakhs and non-current borrowings of Rs. 261.61 lakhs against shareholders' funds of just Rs. 86.04 lakhs. Cash and cash equivalents are thin at Rs. 1.63 lakhs, though operating cash flow stayed positive at Rs. 30.98 lakhs, largely aided by a sharp drop in trade receivables.
Negative for shareholders — the company slipped back into losses, revenue shrank, equity is eroded, and debt is over three times equity, raising sustainability concerns even though the auditor's review was clean.